Metronidazol Polpharma

Metronidazole, the active ingredient in Metronidazol Polpharma, is a nitroimidazole antibiotic presented as an intravenous solution for injection use. It targets anaerobic bacteria and susceptible protozoa, providing effective therapy for a range of serious infections in adult patients, including gynecological and gastrointestinal conditions.

GNH USA supplies Metronidazol Polpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across global markets. The company adheres to stringent manufacturing standards and provides reliable logistics support for timely delivery.

Metronidazole is indicated for several anaerobic bacterial and protozoal infections, acting on the relevant disease pathways. - Bacterial vaginosis: restores normal vaginal flora by eliminating anaerobic overgrowth. - Trichomoniasis: eradicates Trichomonas vaginalis, relieving symptoms and preventing recurrence. - Amoebiasis: destroys Entamoeba histolytica trophozoites, treating intestinal and extra‑intestinal disease. - Clostridioides difficile infection: reduces toxin‑producing anaerobes, aiding resolution of colitis. - Anaerobic bacterial infections: provides bactericidal activity against susceptible anaerobes in various body sites. - Pelvic inflammatory disease: targets anaerobic organisms contributing to PID, helping to resolve infection.

Metronidazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Headache: transient cranial discomfort. - Diarrhea: loose stools that may be self‑limiting. - Metallic taste: temporary alteration of taste perception.

Serious or Rare Side Effects: - Seizures: rare neurologic events requiring immediate attention. - Peripheral neuropathy: numbness or tingling in extremities with prolonged use. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis.

When using Metronidazol Polpharma, clinicians should observe several precautionary measures to ensure safety. - Assess renal function: adjust therapy in patients with significant impairment. - Monitor liver enzymes: watch for hepatotoxicity during prolonged treatment. - Avoid alcohol: discontinue consumption during therapy and for at least 48 hours after the last dose to prevent disulfiram‑like reactions. - Use with caution in pregnancy: classified as Category B, consider risk‑benefit in pregnant women. - Adjust dose in hepatic impairment: consider reduced clearance in liver disease. - Store at controlled room temperature: keep in original container, protect from moisture and light.

Metronidazol Polpharma can interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Alcohol: may cause a disulfiram‑like reaction with flushing, nausea, and tachycardia. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Lithium: can raise lithium concentrations, leading to toxicity.

Moderate Interactions (Monitor Closely): - Phenytoin: may reduce metronidazole levels, decreasing efficacy. - Carbamazepine: enzyme induction may lower metronidazole concentrations. - Oral contraceptives: may have reduced effectiveness; advise additional contraceptive measures.